The Nifty Healthcare index has slumped by 8% to 13,790, plummeting below its moving average, due to concerns about US tariffs. Sun Pharma may experience a 5% earnings decline in FY28, while companies like Aurobindo and Cipla find temporary relief but still face potential policy-related challenges. [Source: Business Standard]
The potential US implementation of a 100% tariff on imported pharmaceuticals could pose a significant disruption for Indian contract development and manufacturing organizations (CDMOs) such as Piramal Pharma, Glenmark, and Sun Pharma. This could lead to market uncertainties for these key players in the pharma industry.
Sun Pharma and Torrent Pharma stand out among large-cap stocks due to their excellent financial health, both earning a perfect Piotroski score of 9. Notably, Sun Pharma's success stems from its robust R&D efforts and global reach, while Torrent Pharma dominates in the Indian and Brazilian markets through growth and strategic acquisitions.
Despite the broader market sell-off, Lupin, Sun Pharma, Torrent Pharma, CCL Products, and Karnataka Bank show remarkable resilience due to robust fundamentals like steady growth, strong pipelines, and strategic moves. Their performance suggests a potential for long-term leadership.
The U.S. has proposed a new tariff on patented drugs, potentially posing risks for companies like Sun Pharma, as the plan exempts generic drugs for now. However, the tariff could impact India's significant generic drug exports to the U.S., valued at $10.5B, due to a potential review in a year.
Major pharmaceutical stocks have experienced a downturn, with notable losses ranging between 3% and 5%. Leading this decline is Sun Pharma on the Nifty index.
The US tariff threat on certain medicines has caused Indian pharma stocks to decline, with notable drops seen in Biocon, Sun Pharma, Glenmark, Aurobindo, and Ipca Labs by 4-5%. The Nifty Pharma index fell by 3.8% due to these concerns about reshoring production.
Sun Pharma experienced a 6% drop in share prices on April 2 due to concerns over potential US tariffs affecting drugmakers. Given that approximately one-third of their sales originate from the US, these tariffs could pose a significant challenge for the company.
Sun Pharma experiences a downturn due to concerns over potential 100% tariffs imposed by the U.S., negatively affecting pharmaceutical stocks.
Despite the overall bearish trend in April, the pharmaceutical sector stands out, with stocks like Astral, Aurobindo Pharma, Sun Pharma, Glenmark, NALCO, and Oil India performing well. Conversely, ICICI Prudential Life and BEL exhibit negative trends, suggesting potential challenges ahead. Investors should keep a close eye on the critical support at 21,700 for the Nifty index.
HC's decision to block Intas from selling a drug resembling Sun Pharma's Bevetyx strengthens Sun Pharma's exclusive rights in the oncology sector, reinforcing their dominant position in this market.
The Delhi High Court has barred Intas from utilizing the trademark 'BEVATAS', due to potential confusion with Sun Pharma's 'BEVETEX'. The court's decision aims to protect public health in the field of oncology drugs, and Sun Pharma has waived any claims for damages.